Hunova® Randomized Controlled Trial for Trunk Control Improvement in Spinal Cord Injured Patients

NCT ID: NCT05887752

Last Updated: 2025-09-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

78 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-06-05

Study Completion Date

2026-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In patients with Spinal Cord Injury (SCI), trunk and therefore postural control (both in statics and dynamics) are impaired, often with strong consequences on daily life activities. Therefore, improvement and reinforcement of trunk control are primary rehabilitation (rehab) goals.

For the evaluation of trunk control in SCI people, still today no tests and scales are definable as gold standards.

Nowadays, for evaluation and rehab purposes of trunk control, balance and proprioception, in both sitting and standing positions, conventional rehabilitation can be supplemented with robotic treatments, e.g. through the Hunova® device (by Movendo Technology). Several studies have demonstrated that conventional rehab associated with robotic training is able to influence functional and motor outcomes in stroke patients, while little evidence is available on SCI patients, also on the number of robotic sessions needed.

The present randomized controlled study primarily aims to demonstrate the effects on trunk control of an integrated rehab treatment (standard plus Hunova®), compared to the standard alone and to gain evidence on the better rehabilitation scheme in terms of number of Hunova® sessions. The correlation between the variation of trunk control, measured by the output data of the Hunova® device itself - ideally more objective - and that assessed through a validated clinical scale, will also be estimated.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In SCI patients trunk and therefore postural control (both in statics and dynamics) are impaired, often with strong consequences on daily life activities. Postural control is defined as the ability to maintain balance despite internal and external perturbations, with the aim of bringing the person's barycenter within his standing area.

Therefore, improvement and reinforcement of trunk control are primary rehab goals.

For the evaluation of trunk control in SCI people, still today no tests and scales are definable as gold standards. Only a few are considered as more reliable, some of them suitable for acute/subacute SCI, some others for chronic SCI. In some published studies, inertial sensors have been used for a more precise evaluation of the Center of Pressure (COP), of the sway area, in relation to the trunk control, but further validation studies are needed. The use of more objective tools could provide additional information on the behavior of SCI people on postural control, thus not only on muscle strength. Of particular interest are the less or more complex compensation strategies implemented and the muscle activation patterns involved in trunk control, assessable through e.g. surface electromyography.

Nowadays, for rehab purposes of trunk control, balance and proprioception, in both sitting and standing position, conventional rehab can be supplemented with robotic treatments, e.g. through the Hunova® device (by Movendo Technology). Several studies have demonstrated that conventional rehab associated with robotic training is able to influence functional and motor outcomes in stroke patients, while little evidence is available on SCI patients, also on the number of robotic sessions needed. The same Hunova® device also allows parameters evaluation by means of its output data.

The present randomized controlled study primarily aims to demonstrate the effects on trunk control of an integrated rehab treatment (standard plus Hunova®), compared to the standard alone and to gain evidence on the better rehab scheme in terms of number of Hunova® sessions. The correlation between the variation of trunk control, measured by the output data of the Hunova® device itself - ideally more objective - and that assessed through a validated clinical scale, will also be estimated.

Randomization will be stratified, based on SCI lesion completeness. A 1:1 allocation ratio will be used for each stratum.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Spinal Cord Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized Controlled Trial (add-on in the first half of the study period)
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors
After selection and enrollment, just before the beginning of the 4-week rehabilitation period, baseline assessments are carried out and patients are randomized. Due to the nature of the Hunova® treatment, blinding of patients and researchers involved in treatment administration will not be possible. Blinding is thus forecast for outcomes' assessors and statisticians only.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard rehab plus 20-session Hunova rehabilitation

Patients will receive the Standard rehabilitation for a period of 4 weeks.

In the same 4 weeks and days, the Hunova® rehabilitation (20 sessions in total) will also be administered.

Group Type EXPERIMENTAL

Standard rehabilitation

Intervention Type OTHER

Carried out 3h/day, 5 days/week at the Montecatone Institute. It implies a multiprofessional approach through:

* physiotherapy;
* occupational therapy;
* sports rehabilitation.

Hunova® rehabilitation

Intervention Type DEVICE

Performed in a dedicated gym of the Montecatone Institute, 1 hour/day, 5 days/week, in the presence of a physiotherapist. Depending on the improvement of the person and of his skills acquisition, the degree of tilting of the Hunova® seat in the various planes may vary.

Standard rehab plus 10-session, delayed, Hunova rehabilitation

Patients will receive the Standard rehabilitation for a period of 4 weeks.

During the last 2 weeks, in the same days, the Hunova® rehabilitation (10 sessions in total) will be also administered.

Group Type OTHER

Standard rehabilitation

Intervention Type OTHER

Carried out 3h/day, 5 days/week at the Montecatone Institute. It implies a multiprofessional approach through:

* physiotherapy;
* occupational therapy;
* sports rehabilitation.

Hunova® rehabilitation

Intervention Type DEVICE

Performed in a dedicated gym of the Montecatone Institute, 1 hour/day, 5 days/week, in the presence of a physiotherapist. Depending on the improvement of the person and of his skills acquisition, the degree of tilting of the Hunova® seat in the various planes may vary.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Standard rehabilitation

Carried out 3h/day, 5 days/week at the Montecatone Institute. It implies a multiprofessional approach through:

* physiotherapy;
* occupational therapy;
* sports rehabilitation.

Intervention Type OTHER

Hunova® rehabilitation

Performed in a dedicated gym of the Montecatone Institute, 1 hour/day, 5 days/week, in the presence of a physiotherapist. Depending on the improvement of the person and of his skills acquisition, the degree of tilting of the Hunova® seat in the various planes may vary.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Spinal Cord Injury of any etiology;
* American Spinal Injury (AIS) grade A or B and American Spinal Injury Association (ASIA) neurological level T1 or below; alternatively AIS grade C or D and ASIA neurological level C4 or below;
* stable clinical conditions;
* maximum distance from the SCI event: 6 months;
* ability to maintain a sitting position for at least 1h continuously;
* subjects capable and collaborating, able to give in person their informed consent.

Exclusion Criteria

* wearer of tracheal cannula, with the need for bronchoaspiration;
* wearer of spine orthosis;
* instability or significant deformity of the spine and/or of the lower limbs;
* presence of paraosteoarthropathy (POA) in development/inflammatory phase;
* presence of ischial Pressure Lesion (PL) of stage ≥ 3, according to the National Pressure Ulcer Advisory Panel / European Pressure Ulcer Advisory Panel (NPUAP/EPUAP) classification;
* need for a lifter for patient transfer;
* body weight ≥ 150 kg.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Montecatone Rehabilitation Institute S.p.A.

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ilaria Baroncini, MD

Role: PRINCIPAL_INVESTIGATOR

Montecatone Rehabilitation Institute S.p.A.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Montecatone Rehabilitation Institute S.p.A.

Imola, BO, Italy

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ilaria Baroncini, MD

Role: CONTACT

+39 0542 632811

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ilaria Baroncini

Role: primary

+39 0542 632811

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MRI_47-2023

Identifier Type: OTHER

Identifier Source: secondary_id

CE AVEC 286-2023-DISP-AUSLIM

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

tSCS + EksoGT in SCI Patients
NCT05921175 NOT_YET_RECRUITING NA
NG004 in Spinal Cord Injury Patients
NCT06817577 RECRUITING PHASE1